Exhibit 10.11
BIOAGE LABS, INC.
September 17, 2024
Eric Morgen
c/o BioAge Labs, Inc.
RE: Continued Employment with BioAge Labs, Inc.
Dear Eric:
This employment letter sets forth the terms confirms your continued employment as Chief Operating Officer of BioAge Labs, Inc., a Delaware Corporation (the “Company” or “BioAge”). You will continue to report to the Chief Executive Officer. This employment letter amends and restates the employment letter entered into between you and BioAge, dated on or about November 28, 2017 and the Executive Severance and Change in Control Agreement, dated on or about January 1, 2023 (the “Prior Agreements”). This letter is effective as of the date on which the Registration Statement covering the initial public offering of the shares of common stock of the Company is declared effective by the U.S. Securities and Exchange Commission (the “IPO Effective Date”).
1. Compensation.
a. Salary. In this position and effective as of the IPO Effective Date, the Company will pay you an annual base salary of $485,000.00 per year, payable in accordance with the Company’s standard payroll schedule. Your pay will be periodically reviewed as a part of the Company’s regular reviews of compensation.
b. Bonus. You will be eligible to receive a cash incentive annual bonus of up to 40% of your base salary, based upon the achievement of both Company and personal goals, for fiscal year 2025. Any annual bonus earned will be paid no later than March 15th of the year following the year in which such bonus was earned. Please note that bonus programs, payouts and criterion are subject to change or adjustment as the business needs at the Company may require.
c. Equity Awards. You currently hold Company equity grants. You will be eligible for future discretionary equity grants at the sole discretion of the Company.
2. Employee Benefits. You will be entitled to participate in employee benefit plans currently and hereafter maintained by the Company of general applicability to other employees of the Company subject to the eligibility requirements of each such benefit plan. The Company, in its sole discretion, may amend, suspend or terminate its employee benefits at any time, with or without notice. In addition, you will be entitled to vacation in accordance with the Company’s vacation policy, as in effect from time to time. We also acknowledge that you are a participant in, or will become a participant in, the Company’s Executive Severance and Change in Control Plan (the “Executive Severance & Change in Control Plan”).
3. Confidentiality Agreement. By signing this letter agreement, you reaffirm the terms and conditions of the confidential information and invention assignment agreement by and between you and the Company.